Estrogen- and tamoxifen-associated effects on brain structure and function

NeuroImage

Volumn 21, Issue 1, 2004, Pages 364-371

  Eberling, Jamie L ^a,b,c   Wu, Christine ^a   Tong Turnbeaugh, Regina ^a   Jagust, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^c NONE   (United States)

Author keywords

Estrogen; Hippocampal atrophy; Tamoxifen

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; GLUCOSE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BRAIN ATROPHY; BRAIN FUNCTION; BRAIN METABOLISM; BRAIN REGION; BRAIN SIZE; BREAST CANCER; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; FRONTAL LOBE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; MEMORY; MENOPAUSAL SYNDROME; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; SEMANTICS; TEMPORAL CORTEX;

EID: 1642492958     PISSN: 10538119     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2003.08.037     Document Type: Article

References (75)

1. Amaducci L.A., Fratiglioni L.et al. Risk factors for clinically diagnosed Alzheimer's disease: a case-control study of an Italian population. Neurology. 36:1986;922-931.
2. Arpels J.C. The female brain hypoestrogenic continuum from the premenstrual syndrome to menopause. J. Reprod. Med. 41:1996;633-639.
3. Asthana S., Baker L.D.et al. High-dose estradiol improves cognition for women with AD: results of a randomized study. Neurology. 57:2001;605-612.
4. Baldereschi M., Di Carlo A.et al. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging. Neurology. 50:1998;996-1002.
5. Barkhem T., Carlsson B.et al. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists. Mol. Pharmacol. 54:1998;105-112.
6. Baxter L.R. Jr., Schwartz J.M.et al. Reduction of prefrontal cortex glucose metabolism common to three types of depression. Arch. Gen. Psychiatry. 46:1989;243-250.
7. Claus J.J., van Harskamp F.et al. The diagnostic value of SPECT with Tc 99m HMPAO in Alzheimer's disease: a population-based study. Neurology. 44:1994;454-461.
8. Cyr M., Thibault C.et al. Estrogen-like activity of tamoxifen and raloxifene on NMDA receptor binding and expression of its subunits in rat brain. Neuropsychopharmacology. 25:2001;242-257.
9. Davidson N.E. Tamoxifen - Panacea or Pandora's box. N. Engl. J. Med. 326:1992;885-886.
10. de Leon M.J., Golomb J.et al. The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR. 14:1993;897-906.
11. DeGregorio M.W. Is tamoxifen chemoprevention worth the risk in healthy women. J. NIH Res. 4:1992;84-87.
12. Diel P. Tissue-specific estrogenic response and molecular mechanisms. Toxicol. Lett. 127:2002;217-224.
13. Dubal D.B., Zhu H.et al. Estrogen receptor alpha, not beta, is a critical link in estradiol-mediated protection against brain injury. Proc. Natl. Acad. Sci. U. S. A. 98:2001;1952-1957.
14. Eberling J.L., Reed B.R.et al. Cognitive correlates of regional cerebral blood flow in Alzheimer's disease. Arch. Neurol. 50:1993;761-766.
15. Eberling J.L., Reed B.R.et al. Effect of estrogen on cerebral glucose metabolism in postmenopausal women. Neurology. 55:2000;875-877.
16. Eberling J.L., Wu C.et al. Preliminary evidence that estrogen protects against age-related hippocampal atrophy. Neurobiol. Aging. 24:2003;725-732.
17. Ernst T., Chang L.et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J. Natl. Cancer Inst. 94:2002;592-597.
18. Frackowiak R.S.J., Pozzili C.et al. Regional cerebral oxygen supply and utilization in dementia: a clinical and physiological study with oxygen-15 and positron tomography. Brain. 104:1981;753-778.
19. Friedland R.P., Budinger T.F.et al. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]Fluorodeoxyglucose. J. Comput. Assist. Tomogr. 7:1983;590-598.
20. Ganz P.A., Castellon S.A.et al. Estrogen, tamoxifen, and the brain. J. Natl. Cancer Inst. 94:2002;547-549.
21. Gould E., Woolley C.S.et al. Gonadal steroids regulate dendritic spine density in hippocampal pyramidal cells in adulthood. J. Neurosci. 10:1990;1286-1291.
22. Green P.S., Simpkins J.W. Neuroprotective effects of estrogens: potential mechanisms of action. Int. J. Dev. Neurosci. 18:2000;347-358.
23. Greene R.A. Estrogen and cerebral blood flow: a mechanism to explain the impact of estrogen on the incidence and treatment of Alzheimer's disease. Int. J. Fert. Women's Med. 45:2000;253-257.
24. Gursoy E., Cardounel A.et al. Tamoxifen protects clonal mouse hippocampal (HT-22) cells against neurotoxins-induced cell death. Neurochem. Int. 40:2002;405-412.
25. Harms C., Lautenschlager M.et al. Differential mechanisms of neuroprotection by 17 beta-estradiol in apoptotic versus necrotic neurodegeneration. J. Neurosci. 21:2001;2600-2609.
26. Heyman A., Wilkinson W.E.et al. Alzheimer's disease: a study of epidemiological aspects. Ann. Neurol. 15:1984;335-341.
27. Horwitz K.B., Jackson T.A.et al. Nuclear receptor coactivators and corepressors. Mol. Endocrinol. 10:1996;1167-1177.
28. Jack C.R., Petersen R.C.et al. MR-based hippocampal volumetry in the diagnosis of Alzheimer's disease. Neurology. 42:1992;183-188.
29. Jack C.R.J., Petersen R.C.et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 52:1999;1397-1403.
30. Kawas C., Resnick S.et al. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging. Neurology. 48:1997;1517-1521.
31. Kelly M.J., Levin E.R. Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol. Metab. 12:2001;152-156.
32. Kennedy S.H., Evans K.R.et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am. J. Psychiatry. 158:2001;899-905.
33. Klein G.J., Teng X.et al. A methodology for specifying PET volumes-of-interest using multi-modality techniques. IEEE Trans. Med. Imag. 16:1997;405-415.
34. Kuiper G.G., Carlsson B.et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:1997;863-870.
35. Kwan L.T., Reed B.R.et al. Effects of subcortical cerebral infarction on cortical glucose metabolism and cognitive function. Arch. Neurol. 56:1999;809-814.
36. Liu Z., Gastard M.et al. Estrogens modulate experimentally induced apoptosis of granule cells in the adult hippocampus. J. Comp. Neurol. 441:2001;1-8.
37. Lundberg J.C., Theobald D.et al. Screening to identify and treat tamoxifen-associated side effects. Cancer Pract. 8:2000;211-214.
38. Maki P.M., Resnick S.M. Longitudinal effects of estrogen replacement therapy on PET cerebral blood flow and cognition. Neurobiol. Aging. 21:2000;373-383.
39. McEwen B. Estrogen actions throughout the brain. Recent Prog. Horm. Res. 57:2002;357-384.
40. McEwen B.S., Tanapat P.et al. Inhibition of dendritic spine induction on hippocampal CA1 pyramidal neurons by a nonsteroidal estrogen antagonist in female rats. Endocrinology. 140:1999;1044-1047.
41. Moore D.S., McCabe G.P. Introduction to the Practice of Statistics. 1989;W.H. Freeman and Company, New York.
42. Moses E.L., Drevets W.C.et al. Effects of estradiol and progesterone administration on human serotonin 2A receptor binding: a PET study. Biol. Psychiatry. 48:2000;854-860.
43. Mulnard R.A., Cotman C.W.et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer's disease: a 1-year randomized controlled trial. JAMA. 283:2000;1007-1015.
44. Mungas D., Reed B.R.et al. Development of psychometrically matched English and Spanish language neuropsychological tests for older persons. Neuropsychology. 14:2000;209-223.
45. Murphy D.D., Segal M. Regulation of dendritic spine density in cultured rat hippocampal neurons by steroid hormones. J. Neurosci. 16:1996;4059-4068.
46. Nystedt M., Berglund G.et al. Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer - self-rated physiological effects and symptoms. Acta Oncol. 39:2000;959-968.
47. Ohkura T., Teshima Y.et al. Estrogen increases cerebral and cerebellar blood flows in postmenopausal women. Menopause. 2:1995;12-18.
48. Paech K., Webb P.et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science. 277:1997;1508-1510.
49. Paganini-Hill A., Clark L.J. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res. Treat. 64:2000;165-176.
50. Paganini-Hill A., Henderson V.W. Estrogen replacement therapy and risk of Alzheimer disease. Arch. Int. Med. 156:1996;2213-2217.
51. Rasgon N.L., Small G.W.et al. Estrogen use and brain metabolic change in older adults. A preliminary report. Psychiatry Res. 107:2001;11-18.
52. Razandi M., Pedram A.et al. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 13:1999;307-319.
53. Resnick S.M., Maki P.M.et al. Effects of estrogen replacement therapy on PET cerebral blood flow and neuropsychological performance. Horm. Behav. 34:1998;171-182.
54. Ron I.G., Inbar M.J.et al. Organic delusional syndrome associated with tamoxifen treatment. Cancer. 69:1992;1415-1417.
55. Schagen S.B., van Dam F.S.et al. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 85:1999;640-650.
56. Shaywitz S.E., Shaywitz B.A.et al. Effect of estrogen on brain activation patterns in postmenopausal women during working memory tasks. JAMA. 281:1999;1197-1202.
57. Sheline Y.I., Sanghavi M.et al. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J. Neurosci. 19:1999;5034-5043.
58. Shughrue P.J., Merchenthaler I. Estrogen is more than just a "sex hormone": novel sites for estrogen action in the hippocampus and cerebral cortex. Front. Neuroendocrinol. 21:2000;95-101.
59. Shumaker S.A., Legault C.et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA. 289:2003;2651-2662.
60. Silva I., Mello L.E.et al. Estrogen, progestogen and tamoxifen increase synaptic density of the hippocampus of ovariectomized rats. Neurosci. Lett. 291:2000;183-186.
61. Small G.W., Ercoli L.M.et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. 97:2000;6037-6042.
62. Soininen H., Partanen K.et al. Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ε4 allele. Neurology. 45:1995;391-392.
63. Sumner B.E., Grant K.E.et al. Effects of tamoxifen on serotonin transporter and 5-hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Mol. Brain Res. 73:1999;119-128.
64. Tanapat P., Hastings N.B.et al. Estrogen stimulates a transient increase in the number of new neurons in the dentate gyrus of the adult female rat. J. Neurosci. 19:1999;5792-5801.
65. Tang M.X., Jacobs D.et al. Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet. 348:1996;429-432.
66. Teter B., Harris-White M.E.et al. Role of apolipoprotein E and estrogen in mossy fiber sprouting in hippocampal slice cultures. Neuroscience. 91:1999;1009-1016.
67. Tohgi H., Takahashi S.et al. Reduced size of right hippocampus in 39- to 80-year-old normal subjects carrying the apolipoprotein E epsilon4 allele. Neurosci. Lett. 236:1997;21-24.
68. van Dam F.S., Schagen S.B.et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. J. Natl. Cancer Inst. 90:1998;210-218.
69. Weiland N.G., Orikasa C.et al. Distribution and hormone regulation of estrogen receptor immunoreactive cells in the hippocampus of male and female rats. J. Comp. Neurol. 388:1997;603-612.
70. Woolley C.S., McEwen B.S. Estradiol mediates fluctuation in hippocampal synapse density during the estrous cycle in the adult rat. J. Neurosci. 12:1992;2549-2554.
71. Wu X., Glinn M.A.et al. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. 847:1999;98-104.
72. Wu C.C., Mungas D.et al. Brain structure and cognition in a community sample of elderly Latinos. Neurology. 59:2002;383-391.
73. Zanardi R., Artigas F.et al. Increased 5-hydroxytryptamine-2 receptor binding in the frontal cortex of depressed patients responding to paroxetine treatment: a positron emission tomography scan study. J. Clin. Psychopharmacol. 21:2001;53-58.
74. Zandi P.P., Carlson M.C.et al. Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA. 288:2002;2123-2129.
75. Zhang L., Rubinow D.R.et al. Estrogen protects against beta-amyloid-induced neurotoxicity in rat hippocampal neurons by activation of Akt. NeuroReport. 12:2001;1919-1923.